tetano
Editor, Senior Moderator
PLoS Med
. 2023 Nov 28;20(11):e1004195.
doi: 10.1371/journal.pmed.1004195. Online ahead of print. Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study
Alexandra B Hogan[SUP] 1 2 [/SUP], Sean L Wu[SUP] 3 [/SUP], Jaspreet Toor[SUP] 2 [/SUP], Daniela Olivera Mesa[SUP] 2 [/SUP], Patrick Doohan[SUP] 2 [/SUP], Oliver J Watson[SUP] 2 4 [/SUP], Peter Winskill[SUP] 2 [/SUP], Giovanni Charles[SUP] 2 [/SUP], Gregory Barnsley[SUP] 2 [/SUP], Eleanor M Riley[SUP] 5 [/SUP], David S Khoury[SUP] 6 [/SUP], Neil M Ferguson[SUP] 2 [/SUP], Azra C Ghani[SUP] 2 [/SUP]
Affiliations
Background: Vaccines have reduced severe disease and death from Coronavirus Disease 2019 (COVID-19). However, with evidence of waning efficacy coupled with continued evolution of the virus, health programmes need to evaluate the requirement for regular booster doses, considering their impact and cost-effectiveness in the face of ongoing transmission and substantial infection-induced immunity.
Methods and findings: We developed a combined immunological-transmission model parameterised with data on transmissibility, severity, and vaccine effectiveness. We simulated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission and vaccine rollout in characteristic global settings with different population age-structures, contact patterns, health system capacities, prior transmission, and vaccine uptake. We quantified the impact of future vaccine booster dose strategies with both ancestral and variant-adapted vaccine products, while considering the potential future emergence of new variants with modified transmission, immune escape, and severity properties. We found that regular boosting of the oldest age group (75+) is an efficient strategy, although large numbers of hospitalisations and deaths could be averted by extending vaccination to younger age groups. In countries with low vaccine coverage and high infection-derived immunity, boosting older at-risk groups was more effective than continuing primary vaccination into younger ages in our model. Our study is limited by uncertainty in key parameters, including the long-term durability of vaccine and infection-induced immunity as well as uncertainty in the future evolution of the virus.
Conclusions: Our modelling suggests that regular boosting of the high-risk population remains an important tool to reduce morbidity and mortality from current and future SARS-CoV-2 variants. Our results suggest that focusing vaccination in the highest-risk cohorts will be the most efficient (and hence cost-effective) strategy to reduce morbidity and mortality.
. 2023 Nov 28;20(11):e1004195.
doi: 10.1371/journal.pmed.1004195. Online ahead of print. Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study
Alexandra B Hogan[SUP] 1 2 [/SUP], Sean L Wu[SUP] 3 [/SUP], Jaspreet Toor[SUP] 2 [/SUP], Daniela Olivera Mesa[SUP] 2 [/SUP], Patrick Doohan[SUP] 2 [/SUP], Oliver J Watson[SUP] 2 4 [/SUP], Peter Winskill[SUP] 2 [/SUP], Giovanni Charles[SUP] 2 [/SUP], Gregory Barnsley[SUP] 2 [/SUP], Eleanor M Riley[SUP] 5 [/SUP], David S Khoury[SUP] 6 [/SUP], Neil M Ferguson[SUP] 2 [/SUP], Azra C Ghani[SUP] 2 [/SUP]
Affiliations
- PMID: 38016000
- DOI: 10.1371/journal.pmed.1004195
Background: Vaccines have reduced severe disease and death from Coronavirus Disease 2019 (COVID-19). However, with evidence of waning efficacy coupled with continued evolution of the virus, health programmes need to evaluate the requirement for regular booster doses, considering their impact and cost-effectiveness in the face of ongoing transmission and substantial infection-induced immunity.
Methods and findings: We developed a combined immunological-transmission model parameterised with data on transmissibility, severity, and vaccine effectiveness. We simulated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission and vaccine rollout in characteristic global settings with different population age-structures, contact patterns, health system capacities, prior transmission, and vaccine uptake. We quantified the impact of future vaccine booster dose strategies with both ancestral and variant-adapted vaccine products, while considering the potential future emergence of new variants with modified transmission, immune escape, and severity properties. We found that regular boosting of the oldest age group (75+) is an efficient strategy, although large numbers of hospitalisations and deaths could be averted by extending vaccination to younger age groups. In countries with low vaccine coverage and high infection-derived immunity, boosting older at-risk groups was more effective than continuing primary vaccination into younger ages in our model. Our study is limited by uncertainty in key parameters, including the long-term durability of vaccine and infection-induced immunity as well as uncertainty in the future evolution of the virus.
Conclusions: Our modelling suggests that regular boosting of the high-risk population remains an important tool to reduce morbidity and mortality from current and future SARS-CoV-2 variants. Our results suggest that focusing vaccination in the highest-risk cohorts will be the most efficient (and hence cost-effective) strategy to reduce morbidity and mortality.